Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Bio-Medical Pharmaceutical Manufacturing Corporation
WARNING LETTER
•Bio-Medical Pharmaceutical Manufacturing Corporation•August 29, 2025

Bio-Medical Pharmaceutical Manufacturing Corporation – FDA Warning Letter, Aug 29, 2025

Record Details

The FDA issued a Warning Letter to Bio-Medical Pharmaceutical Manufacturing Corporation following an inspection from August 25 to 29, 2025. The letter details significant violations of Current Good Manufacturing Practice (CGMP) regulations (21 CFR parts 210 and 211) and the Federal Food, Drug, and Cosmetic Act, rendering the firm's drug products adulterated. Key issues include a failure to establish adequate procedures to prevent microbiological contamination in sterile drug products, lacking classified cleanrooms, appropriate aseptic conditions, and environmental controls. The company also failed to ensure proper design and maintenance of manufacturing equipment, notably their water system, and lacked essential process and cleaning validation studies. Furthermore, Bio-Medical did not conduct appropriate laboratory testing, including sterility testing, for drug product release, compromising product identity, strength, and purity. The firm also failed to fulfill drug listing obligations for its "(b)(4) Solution" product under 21 CFR 207. The FDA strongly recommended engaging a qualified CGMP consultant to evaluate operations and assist with compliance. Required actions include submitting comprehensive risk assessments, detailed remediation plans, system validation reports, and a corrective and preventive action (CAPA) plan for all identified violations within 15 working days. The company must also conduct full chemical and microbiological testing of retain samples for distributed products and clarify its intentions for manufacturing sterile drugs. Prompt correction is essential to avoid further regulatory or legal action.

Company
Bio-Medical Pharmaceutical Manufacturing Corporation
Inspection date
August 29, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Yanzhuan Zheng
  • Tina Smith (Director)
View Company Profile

ID · c3f49883-6cdd-4757-8d03-40ec8016fdd0

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)FD&C Act 510(j)21 U.S.C. 360(j)21 CFR 207FD&C Act 301(p)21 U.S.C. 331(p)21 CFR 211.113(b)

Full citation text and observation details available on the Dashboard.

Other documents for Bio-Medical Pharmaceutical Manufacturing Corporation
  • 483 - 2025-08-29August 29, 2025
  • 483 - 2020-01-23January 23, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bio-Medical Pharmaceutical Manufacturing Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.